International Business has occupied a position of prominence in Indoco’s strategy and it's long term vision. With the introduction of patent regime in India, the prospects for International Business have boosted up. With the approval of the Solid Dosages facility in Goa in the year 2003, Indoco has entered into the Regulated markets with Contract Manufacturing Services. Prior to 2003, Indoco was catering to the Emerging markets with supplies of it's branded generics.
Today, we can boast of world class manufacturing facilities, which have been approved by US-FDA, UK-MHRA, Darmstadt-Germany, ANVISA-Brazil & MCC South Africa.
We have backward integrated into API synthesis & manufacturing by setting up a world-class, state-of-the-art R & D centre for APIs at Rabale and by acquisition of LaNOVA Chem Pvt. Ltd. an API manufacturing facility. This backward integration helps us to control over consistent supply of the APIs for our ongoing projects and future projects for Regulated markets.
Our excellence in manufacturing of APIs (Active Pharmaceutical Ingredients) & FDFs ( Finished Dosage Forms) and Contract Research activities has enabled us to expand our presence in 35 countries in Regulated & Emerging markets.